Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Finasteride versus dutasteride: a real-world economic evaluation.

Thomas C Fenter1, M Chris Runken, Libby Black

  • 1Blue Cross & Blue Shield of Mississippi, Jackson, MS 39215, USA. tfenter@bcbsms.com

The American Journal of Managed Care
|February 14, 2007
PubMed
Summary

Dutasteride treatment resulted in lower medical costs compared to finasteride for benign prostatic hyperplasia patients. This economic difference, driven by reduced hospitalizations, should inform healthcare plan evaluations of these 5-alpha reductase inhibitors.

Related Concept Videos

Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of intravenous immunoglobulin therapy on resource utilization associated with viral respiratory tract infections.

Frontiers in immunology·2025
Same author

Improving the Likelihood of Identifying Alpha-1 Antitrypsin Deficiency Among Patients With COPD: A Novel Predictive Model Using Real-World Data.

Chronic obstructive pulmonary diseases (Miami, Fla.)·2024
Same author

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial.

Current Alzheimer research·2024
Same author

Understanding treatment goals and their application in clinical trial design for patients with Alzheimer disease and caregivers.

Drugs in context·2024
Same author

Application of a Novel Endpoint Staging Framework: Proof of Concept in the AMBAR Study.

Journal of Alzheimer's disease : JAD·2024
Same author

Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease.

Expert review of neurotherapeutics·2022

Area of Science:

  • Pharmacoeconomics
  • Urology

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition in aging men.
  • 5-alpha reductase inhibitors (5ARIs) like dutasteride and finasteride are primary treatments for BPH.
  • Understanding the economic impact of these treatments is crucial for healthcare providers.

Purpose of the Study:

  • To compare the economic differences between dutasteride and finasteride treatments within the first year.
  • To analyze medical costs associated with enlarged prostate (EP)-specific care for patients on dutasteride versus finasteride.

Main Methods:

  • Retrospective analysis of a large, nationally representative healthcare claims database.
  • Inclusion of male patients over 50 with BPH initiating 5ARI treatment (dutasteride or finasteride) between 1999-2005.

Related Experiment Videos

Last Updated: Jul 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

  • Matching of patients (1:3 dutasteride:finasteride) based on age, acute urinary retention, EP-specific charges, and follow-up duration.

    • Main Results:

    • Overall monthly EP-specific charges were $121.04, with inpatient hospitalizations (39.1%) and physician visits (33.6%) being major cost drivers.
    • Patients treated with dutasteride incurred significantly lower monthly EP-specific charges ($105.67) compared to finasteride ($126.17), a difference of $20.50 (P = .0007).
    • The cost reduction for dutasteride users was primarily due to lower inpatient hospitalization expenses.

    Conclusions:

    • Dutasteride treatment is associated with lower monthly medical costs than finasteride for BPH patients.
    • Healthcare plans should consider these pharmacoeconomic differences, alongside drug costs, when selecting 5ARIs.
    • These findings highlight the importance of evaluating total healthcare utilization costs in BPH management.